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N-Terminal Probrain Natriuretic
Peptide Is a Stronger Predictor of
Cardiovascular Mortality Than
C-Reactive Protein and Albumin
Excretion Rate in Elderly PatientsWith
Type 2 Diabetes









PAOLO CAVALLO PERIN, MD1
GABRIELLA GRUDEN, PHD1
OBJECTIVEdTo study whether N-terminal probrain natriuretic peptide (NT-proBNP) is a
short-term independent predictor of both all-cause and cardiovascular (CV) mortality in type 2
diabetic patients and to establish whether albuminuria and C-reactive protein (CRP) affect this
relationship.
RESEARCH DESIGN ANDMETHODSdThe prospective study included 1,825 type 2
diabetic patients from the population-based cohort of the Casale Monferrato study. CV risk
factors, preexisting CVD, and NT-proBNP levels were evaluated at baseline. All-cause and CV
mortality were assessed 5.5 years after baseline examination. Multivariate Cox proportional
hazards modeling was used to estimate mortality hazard ratios (HRs).
RESULTSdDuring the follow-up period, 390 people died (175 for CVD) out of 9,101 person-
years of observations. A significantly increased mortality risk by quartiles of NT-proBNP was
observed (test for trend, P , 0.001). NT-proBN P values .91 pg/mL conferred HRs of 2.05
(95% CI 1.47–2.86) for all-cause and 4.47 (2.38–8.39) for CV mortality, independently of CV
risk factors, including CRP and albumin excretion rate (AER). The association was also signif-
icant for modest rises in NT-proBNP levels and in patients without microalbuminuria and CVD
at baseline (upper quartiles HRs 3.82 [95% CI 1.24–13.75]) and 3.14 [1.00–9.94]). Albumin-
uria andNT-proBNP had an additive effect onmortality, though the association was stronger for
NT-proBNP.
CONCLUSIONSdNT-proBNP is a strong independent predictor of short-term CVmortality
risk in elderly people with type 2 diabetes, including those without preexisting CVD. This
association is evident even in people with slightly increased values, is not modified by CRP,
and is additive to that provided by AER.
Diabetes Care 36:2677–2682, 2013
Cardiac natriuretic peptides, atrial(ANP) and B-type (BNP), are se-creted in response to myocardial
stretching induced by volume overload.
They play an important role in the control
of blood pressure and both sodium and
water balance by regulating both the
renin-angiotensin and the sympathetic
nervous systems (1). N-terminal probrain
natriuretic peptide (NT-proBNP) is the
inactive molecule resulting from cleavage
of BNP prohormone (1). In the general
population, circulating levels of NT-
proBNP are used in the diagnosis of acute
heart failure (2) and correlate with left
ventricular dilatation, remodeling, and
dysfunction (3).
NT-proBNP is strongly associated
with the risk of cardiovascular (CV)
disease (CVD) in both high-risk patients
with established CVD and the general
population (4–6). Patients with type 2 di-
abetes have an increased risk of vascular
complications, which cannot be com-
pletely accounted for by conventional
risk factors. Clinic-based studies have
shown a role of NT-proBNP as a bio-
marker of CVD in diabetic patients;
however, lack of prospective population-
based studies does not allowdata extrapo-
lation to the entire diabetic population
(7–10).
In type 2 diabetic patients, albumin-
uria is a well-established predictor of CV
morbidity and mortality. In addition,
C-reactive protein (CRP) is independently
associated with short-term mortality risk
even in type 2 diabetic individuals with-
out preexisting CVD and albuminuria
(11,12). However, there are no prospec-
tive data on the relationship between
CRP, albuminuria, and NT-proBNP on
CV mortality in people with type 2 dia-
betes. Our aim was to investigate in the
population-based cohort of type 2 diabetic
patients from the Casale Monferrato
study whether NT-proBNP is a short-
term predictor of all-cause and CV mor-
tality, independently of CV risk factors,
and whether albuminuria and CRP affect
the relationship between NT-proBNP
and short-term mortality.
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The study base was comprised of 3,249
type 2 diabetic patients: residents in the
year 2000 in the town of CasaleMonferrato
in the northwest of Italy (93,477 inhab-
itants) (13). Patients were identified
based on independent data sources (dia-
betes clinics; administrative data sources),
using the capture-recapture method,
with a high degree of estimated ascertain-
ment (95%). The date of diabetes diagno-
sis was retrieved and recorded for all
recruited subjects. As previously de-
scribed in detail, patients were interviewed
and examined and blood samples col-
lected after overnight fasting (13). Ethics
committee approval was obtained, and
all subjects provided written informed
consent.
Smoking status was classified as cur-
rent smoker, never smoker, or ex-smoker
(smoking cessation at least a month prior
to the visit). Hypertension was defined as
systolic blood pressure.140mmHg and/
or diastolic blood pressure.90mmHg or
treatment with antihypertensive drugs.
CVD was defined as a positive medical
history of a CV event, including myocar-
dial infarction, angina pectoris, coronary
artery bypass graft and stroke, or ische-
mic changes on a resting 12-lead electro-
cardiogram, classified according to the
Minnesota Code. The World Health Or-
ganization Rose questionnaire was also
administered, and people with symptoms
suggestive of CVD underwent further
investigations to confirm the diagnosis.
Congestive heart failure was clinically di-
agnosed based on medical history, phys-
ical examination, and drug treatment.
Blood samples were analyzed at the
Central Laboratory (13). Triglycerides,
total cholesterol, HDL cholesterol, apo-
lipoprotein (apo)A1, apoB, serum cre-
atinine, and HbA1c (reference range
3.8–5.5%) were measured by standard
laboratory techniques. LDL cholesterol
was calculated from Friedewald formula
when triglyceride values were ,4.48
mmol/L. Glomerular filtration rate was es-
timated using the four-component abbre-
viated equation from the MDRD Study
(14). Subjects with an estimated glomer-
ular filtration rate (eGFR) ,60 mL/min/
1.73 m2 were defined as having chronic
kidney disease. High-sensitivity CRP
was measured by immunoturbidimetry
(Roche Diagnostics, Mannheim, Germany)
(coefficient of variation 0.5%). Albumin
excretion rate (AER) was measured by
nephelometry (Behring Nephelometer
Analyzer; Behring Institute, Marburg,
Germany) (coefficient of variation 4%)
on single overnight urine collections and
categorized as either normoalbuminuria
(,20 mg/min) or micro- or macroalbumi-
nuria ($20 mg/min). Serum NT-proBNP
levels were measured by a two-site sand-
wich electrochemiluminescence immu-
noassay (Elecsys proBNP II; Roche
Diagnostics), using a Modular Analytics
Evo analyzer with an E170module (Roche)
as previously described (15). The intra-
assay variation was ,3.0%, and total co-
efficient of variation ranges were between
2.2 and 5.8% in low and high ranges of
NT-proBNP.
Follow-up study
Six years after baseline examinations,
mortality data up to 31 December 31
2006were obtained from the demograph-
ical files of towns of residence and both
hospital and autopsy records. Only one
patient was lost to follow-up. Underlying
causes of death were derived and coded
by two authors according to ICD-9 with
100% agreement. CV mortality was de-
fined by ICD-9 codes 390–459.
Statistical analysis
Variables distributed normally are pre-
sented as mean and SD, while variables
with skewed distribution (triglycerides,
AER, CRP, and NT-proBNP) were ana-
lyzed after logarithmic transformation
and results presented as geometric means
and 95% CIs. Comparisons were per-
formed using the Student t test and the x2
test as appropriate. Pearson correlation
and multiple linear regression were used
to assess relationships and covariance
analysis to adjust log NT-proBNP values
for potential confounders.
Mortality rates were calculated divid-
ing the number of deaths, occurring
during the study period, by the number
of person-years of observation. Cox pro-
portional hazards modeling was used
to estimate the hazard ratios (HRs) and
95% CIs of CV and all-cause mortality by
NT-proBNP values independently of con-
ventional and new risk factors. Models for
log NT-proBNP as a continuous measure
were run to assess the multiplicative in-
crease of each increment of NT-proBNP
to mortality risk. Analyses were also
performed using quartiles of NT-proBNP
value distribution to examine the shape
of the relationship between NT-proBNP
values andmortality. In order to assess the
incremental association of NT-proBNP
with respect to CV risk factors, all models
were adjusted for age, sex, diabetes dura-
tion (model 1), hypertension, HbA1c,
smoking, apoA1/apoB, eGFR, AER,
CVD, diabetes treatment (model 2), and
CRP (model 3). Models were constructed
with variables as continuous measures ex-
cept AER (, 20 vs. $20 mg/min) and
eGFR (,60 vs. $60 mL/min/1.73 m2) to
provide maximum power for detecting
an association between NT-proBNP and
mortality. BMI and antihyperglycemic
treatment (diet, oral drugs, and insulin)
were also included in models 2 and 3, as
they might provide residual confounding
of the relationship between NT-proBNP
and mortality. In addition, we allowed
any of the following variables to enter
the model if they added significantly or
modified HRs of NT-proBNP: waist cir-
cumference; uric acid; total, LDL, and
HDL cholesterol; triglycerides; fibrinogen;
systolic and diastolic blood pressure; and
antihypertensive treatment. Stratified
mortality analysis by CVD and AER (,20
vs. $20 mg/min) at baseline was also per-
formed. We tested for linear trends across
categorical variables by entering a single
ordinal term into the Cox regression
model. The proportional hazard assump-
tions of explanatory variables were assessed
on the basis of Schoenfeld residuals. The
likelihood ratio test was used to assess the
statistical significance of examined varia-
bles in nestedmodels.We also carried out
analyses that included terms for the in-
teraction between NT-proBNP and AER.
A P value of,0.05 was considered to in-
dicate statistical significance. Analyses
were performed with STATA software,
version 10.0.
RESULTSdOf the 3,249 type 2 dia-
betic subjects enrolled in the Casale Mon-
ferrato Study, 1,825 (56.2%) patients
showed no clinical evidence of heart
failure and had samples available for
NT-proBNP measurements. Compared
with the entire cohort, selected patients
were younger (67.6 6 10.5 vs. 71.0 6
12.2 years, respectively; P , 0.0001)
and had slight lower diabetes duration
(10.7 6 8.0 vs. 11.5 6 8.4 years; P =
0.02) and negligibly lower HbA1c values
(7.06 1.8 vs. 7.26 1.8%, 536 19.7 vs.
55 6 19.7 mmol/mol; P = 0.01) but sim-
ilar systolic blood pressure (146.06 16.4
vs. 145.0 6 17.2 mmHg; P = 0.16) and
diastolic blood pressure (82.6 6 8.2 vs.
83.26 8.2mmHg; P = 0.10) levels. At the
baseline examination, most of the
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subjects (64.0%) were elderly, being$65
years old at recruitment.
The distribution of NT-proBNP val-
ues was right skewed with a median value
of 90 pg/mL (interquartile range 39–200).
As expected, NT-proBNP levels were
higher in women than in men (103.1
pg/mL [interquartile range 48–215]) vs.
76.2 pg/mL [30–185], P , 0.0001]),
but differences disappeared after adjust-
ment for age. In addition, overweight/
obese patients had lower NT-proBNP val-
ues (77.3 vs. 112.7, P, 0.001) compared
with normal-weight subjects, even after
adjustment for age and sex (P = 0.003).
Baseline characteristics of the 1,825 re-
cruited patients by quartiles of NT-proBNP
values are reported in Table 1. At baseline,
there was a direct significant correlation
between NT-proBNP levels and age,
systolic blood pressure, HDL cholesterol,
uric acid, log-AER, fibrinogen, and log
CRP. A significant negative correlation
was found with plasma glucose, BMI,
waist circumference, total and LDL cho-
lesterol, apoB/apoA1, triglycerides, and
eGFR (data not shown). In multiple lin-
ear regression, variables independently
associated with log NT-proBNP were
age, apoB/apoA1, eGFR, log AER, fibrin-
ogen, and log CRP, and they accounted
for 35% of NT-proBNP variability (P ,
0.0001).
During the 5-year follow-up period
(median 5.5 years [range 0.1–7.3]), 390
people died out of 9,101.6 person-years.
CV mortality accounted for 175 (44.9%)
deaths and out of them 101 deaths oc-
curred in subjects without preexisting
CVD. All-cause and CV mortality rates
per 1,000 person-years were 42.8 (95%
CI 38.8–47.3) and 19.2 (16.6–22.3), re-
spectively. Kaplan-Meier curves for over-
all mortality according to quartiles of
NT-proBNP are shown in Fig. 1 (log-
rank test P , 0.0001)
In multivariable Cox proportional
hazard models for all-cause and CV mor-
tality, HRs were significantly higher in
persons with NT-proBNP values in the
third and fourth quartiles compared with
persons with values in the lowest quar-
tile. This was only slightly reduced by
multiple adjustment for CV risk factors,
potential confounders, and preexisting
CVD (Table 2, models 1 and 2). After fur-
ther adjustment for CRP (Table 2, model
3), HRs for all-cause mortality were
slightly reduced, while HRs for CV mor-
tality were left unchanged. Trends of HRs
Table 1dBaseline characteristics of persons with type 2 diabetes of the Casale Monferrato study by NT-proBNP quartiles
Quartiles of NT-proBNP (pg/mL)
P,41 41–90 91–200 .200
n 471 450 449 455
Men 286 (60.7) 222 (49.3) 179 (39.9) 207 (45.5) ,0.0001
Age (years) 60.4 6 9.3 65.8 6 9.5 70.3 6 8.7 74.4 6 8.8 ,0.0001
Duration of diabetes (years) 8.2 6 6.5 10.5 6 7.8 11.2 6 7.9 13.0 6 8.8 ,0.0001
BMI (kg/m2) 29.4 6 5.4 28.9 6 5.1 28.6 6 4.8 27.9 6 5.2 0.0005
Waist circumference (cm) 99.1 6 12.1 98.5 6 12.4 97.5 6 11.9 96.9 6 12.1 0.04
Systolic blood pressure (mmHg) 143.5 6 14.8 144.9 6 15.8 148.6 6 16.4 147.2 6 17.1 ,0.0001
Diastolic blood pressure (mmHg) 82.8 6 7.8 82.2 6 7.7 83.0 6 8.6 82.5 6 8.7 0.40
Hypertension 385 (82.1) 395 (88.2) 419 (93.3) 433 (95.2) ,0.0001
Plasma glucose (mg/dL) 180.4 6 54.1 172.5 6 53.5 172.7 6 53.8 172.0 6 60.6 0.06
HbA1c (%) 6.9 6 1.7 7.0 6 1.8 7.1 6 1.8 7.0 6 1.8 0.57
HbA1c (mmol/mol) 52 6 18.6 53 6 19.7 54 6 19.7 53 6 19.7 0.57
Total cholesterol (mg/dL) 215.3 6 39.7 214.3 6 38.7 213.2 6 38.6 205.9 6 42.1 0.001
LDL cholesterol (mg/dL) 131.4 6 34.7 130.0 6 32.3 127.7 6 32.3 122.7 6 36.2 0.001
HDL cholesterol (mg/dL) 53.0 6 14.3 54.8 6 14.0 57.0 6 15.2 54.8 6 16.2 0.001
Triglycerides (mg/dL) 138 (94–193) 129 (92–179) 124 (87–171) 124 (85–171) 0.0008
ApoA1 (mg/dL) 149.6 6 41.6 159.6 6 37.1 160.5 6 36.2 155.1 6 34.9 ,0.0001
ApoB (mg/dL) 104.6 6 26.7 104.3 6 26.0 102.3 6 25.4 99.3 6 28.0 0.0009
ApoB/apoA1 0.77 6 0.35 0.71 6 0.34 0.68 6 0.30 0.68 6 0.27 ,0.0001
Serum creatinine (mg/dL) 0.79 (0.67–0.92) 0.80 (0.68–0.93) 0.85 (0.69–1.01) 0.97 (0.77–1.12) ,0.0001
eGFR (mL/min/1.73 m2) 97.1 6 22.3 91.3 6 24.7 82.6 6 24.2 73.3 6 24.2 ,0.0001
CRP (mg/L) 0.24 (0.12–0.52) 0.24 (0.11–0.50) 0.30 (0.13–0.70) 0.35 (0.15–0.79) ,0.0001
Fibrinogen (g/L) 357.9 6 56.6 372.5 6 67.5 381.8 6 74.7 408.5 6 107.9 ,0.0001
Uric acid (mg/dL) 5.34 6 1.45 5.39 6 2.36 5.68 6 1.62 6.08 6 1.73 ,0.0001
AER (mg/min) 11.0 (4.1–21.8) 11.8 (4.2–24.9) 11.8 (4.3–24.8) 21.9 (6.7–51.9) ,0.0001
Micro- and macroalbuminuria 111 (26.9) 104 (28.0) 100 (28.3) 144 (43.0) ,0.0001
CVD 61 (12.9) 74 (16.4) 109 (24.3) 159 (34.9) ,0.0001
Smoking ,0.0001
Former smoker 155 (33.8) 131 (30.3) 105 (24.0) 133 (30.2)
No 90 (19.6) 73 (16.9) 52 (11.9) 47 (10.7)
Glucose-lowering treatment ,0.0001
Oral drugs 371 (79.6) 335 (75.3) 301 (67.6) 302 (68.0)
Insulin 27 (13.1) 44 (21.4) 61 (29.6) 74 (35.9)
Data are means 6 SD, n (%), or geometric mean (interquartile range).
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across NT-proBNP quartiles were statis-
tically significant in all examined models.
NT-proBNP values greater than the me-
dian value (91 pg/mL) conferred fully ad-
justed HRs of 2.05 (95% CI 1.47–2.86)
for all-cause mortality and 4.47 (2.38–
8.39) for CV mortality (Table 2, model
3). NT-proBNP conferred higher HRs
than both AER and CRP. Indeed, in the
final model 3, micro- and macroalbumi-
nuria conferred HRs of 1.37 (1.03–1.84)
and 1.29 (0.82–2.05) for all-cause and
CV mortality, respectively, and log CRP
of 1.17 (1.04–1.32) and 1.06 (0.88–
1.29). Similarly, analyses performed
using log NT-proBNP as a continuous
variable showed a 50% increase risk of
all-cause mortality and a 69% increase risk
of CV mortality for each increment of NT-
proBNP (1 natural logarithm = 0.35 pg/mL)
in the fully adjusted models (Table 2,
model 3). In the subgroup of patients
without CVD at baseline, results were
comparable with those obtained in the
whole cohort (Table 2). Of relevance, in
patients without micro/macroalbumi-
nuria and CVD at baseline, HRs for CV
mortality in the second and in the third
quartiles of NT-proBNP were 3.82
(1.24–13.75) and 3.14 (1.00–9.94),
respectively.
As shown in Table 3, when fully ad-
justed models were fitted replacing NT-
proBNP and AER terms with an indicator
variable with four categories defined by
their joined effects, we found that with
respect to the reference category (AER
,20 mg/min and NT-proBNP ,91 pg/
mL), HRs of both CV and all-cause mor-
tality were significantly increased in pa-
tients with NT-proBNP $91 pg/mL,
irrespective of presence or absence of
micro- and macroalbuminuria, but no
evidence of an effect modification was
Figure 1dKaplan-Meier survival curves for type 2 diabetic patients from the Casale Monferrato
study categorized by NT-proBNP quartiles at baseline. Log-rank test P , 0.0001.
Table 2dHRs (95% CI) of 5-year all-cause and CV mortality in persons with type 2 diabetes of the Casale Monferrato study
All-cause mortality CV mortality
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
All patients
Log NT-proBNP 1.67 (1.54–1.81) 1.55 (1.37–1.74) 1.50 (1.33–1.70) 1.85 (1.64–2.09) 1.70 (1.41–2.06) 1.69 (1.39–2.05)
NT-proBNP (pg/mL)
,41 1.00 1.00 1.00 1.00 1.00 1.00
41–90 1.50 (0.98–2.29) 1.42 (0.91–2.21) 1.14 (0.68–1.92) 2.02 (0.88–4.65) 1.40 (0.45–4.34) 1.42 (0.46–4.40)
91–200 2.12 (1.41–3.18) 1.93 (1.26–2.95) 1.62 (0.99–2.67) 4.31 (2.00–9.30) 4.04 (1.50–10.89) 4.03 (1.49–10.86)
.200 4.72 (3.22–6.92) 4.20 (2.81–6.29) 2.95 (1.83–4.78) 10.10 (4.80–21.27) 7.67 (2.88–20.38) 7.52 (2.82–2.04)
P for trend ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001
,91 1.00 1.00 1.00 1.00 1.00 1.00
$91 2.60 (2.04–3.32) 2.17 (1.57–3.02) 2.05 (1.47–2.86) 4.42 (2.88–6.78) 4.58 (2.45–8.57) 4.47 (2.38–8.39)
Patients without CVD
Log NT-proBNP 1.57 (1.41–1.74) 1.50 (1.29–1.74) 1.42 (1.22–1.65) 1.70 (1.43–2.03) 1.57 (1.20–2.06) 1.49 (1.14–1.96)
NT-proBNP (pg/mL)
,41 1.00 1.00 1.00 1.00 1.00 1.00
41–90 1.33 (0.83–2.15) 1.09 (0.59–2.00) 1.07 (0.59–1.97) 1.26 (0.49–3.25) 0.87 (0.23–3.32) 0.87 (0.23–3.32)
91–200 2.11 (1.34–3.33) 2.15 (1.22–3.78) 2.00 (1.14–3.53) 3.04 (1.30–7.10) 3.29 (1.06–10.24) 3.13 (1.00–9.72)
.200 3.70 (2.37–5.76) 2.81 (1.58–4.99) 2.50 (1.40–4.46) 5.16 (2.22–12.00) 3.54 (1.09–11.57) 3.20 (0.98–10.40)
P for trend ,0.0001 ,0.0001 ,0.0001 ,0.0001 0.003 0.008
,91 1.00 1.00 1.00 1.00 1.00 1.00
$91 2.36 (1.77–3.15) 2.32 (1.57–3.43) 2.13 (1.43–3.16) 3.40 (2.00–5.77) 3.69 (1.69–8.06) 3.44 (1.56–7.56)
Model 1 adjusted for age, sex, and diabetes duration. Model 2 adjusted for model 1 adjustments plus BMI, hypertension (yes/no), apoB/apoA1, HbA1c, smoking (no,
former, and current), CVDs (yes/no), eGFR (,60 or $60 mL/min/1.73 m2), AER, and diabetes treatment (diet/oral drugs/insulin). Model 3 adjusted for model 2
adjustments plus CRP.
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found. Indeed, the expected HRs ob-
tained by the multiplication of the HRs
in each category of NT-proBNP and
AER were higher than the observed
HRs. No significant interactions were
found between AER and NT-proBNP val-
ues (P = 0.30 for all-cause mortality and
P = 0.58 for CV mortality). In patients
without micro- or macroalbuminuria
and CVD at baseline (Table 3), NT-proBNP
values $91 pg/mL conferred a statisti-
cally significant twofold increased risk
of all-cause mortality and a fivefold in-
creased risk of CV mortality compared
with patients with lower NT-proBNP val-
ues, and an additive effect of AER and
NT-proBNP on both all-cause and CV
mortality was also observed.
CONCLUSIONSdOur population-
based study indicates that NT-proBNP
is a strong independent predictor of
short-term CVmortality in type 2 diabetic
people and that this effect is evident even
in normoalbuminuric patients without
CVD at baseline. The association between
NT-proBNP andmortality was additive to
that provided by micro- and macroalbu-
minuria, was notmodified by acute-phase
inflammation markers, and was evident
even in people with slightly increased NT-
proBNP values. Both conventional and
new CV risk factors (AER, eGFR, and uric
acid) had a quite limited effect on the
strength of the association between NT-
proBNP and death, providing evidence
that they do not act as mediators or as
confounders. This finding suggests that
they might be minimally involved in the
pathogenetic cascade linking increased
NT-proBNP values and CV mortality.
Our findings are original, and to our
knowledge no previous prospective
population-based study has examined in
patients with type 2 diabetes the predic-
tive role of NT-proBNP and its potential
interrelationships with the main markers
of CV mortality in these patients, AER and
CRP. Our results are consistent and ex-
pand observations from the few clinic-
based prospective studies examining this
issue (7–9). In the Danish cohort, includ-
ing 315 diabetic patients followed up to 15
years, NT-proBNP values in the upper ter-
tile only increased significantly the HR for
all-cause mortality after adjustment for
risk factors (7). Another study including
1,071 diabetic patients followed for up to
3 years showed a linear multiplicative as-
sociation between log NT-proBNP and
mortality, but no dose response was ana-
lyzed (9). In our study, NT-proBNP was
included in multivariate analyses both as
continuous variable and as quartiles, al-
lowing us to show that even minimally
elevated values in the third quartile (91–
200 pg/mL) conferred a statistically in-
creased risk. With respect to the median
NT-proBNP value of 91 pg/mL, higher val-
ues conferred a significant twofold in-
creased risk of overall mortality and a
threefold increased risk of CV mortality,
which was only slightly affected by adjust-
ment for traditional and new risk factors,
including AER, CRP, fibrinogen, uric acid,
and eGFR.
NT-proBNP was a significant predic-
tor of mortality also in the subgroup of
patients without CVD at baseline. This
finding is in agreement with a recent
prospective population-based study per-
formed in old men from the general
population (16) and suggests that NT-
proBNP may be useful in primary preven-
tion for the identification of patients
with a hitherto unknown high risk of
death.
In type 2 diabetic patients, elevated
urinary AER is considered the most con-
sistent independent predictor of adverse
outcomes (17) and CRP is independently
associated with short-term mortality risk
(11). Nonetheless, in the current study
NT-proBNP was a stronger predictor of
mortality than albuminuria and CRP, par-
ticularly for CV deaths. In keeping with
this finding, a recent clinic-based pro-
spective study in diabetic patients repor-
ted that NT-proBNP was superior to
albuminuria for predicting cardiac events
(9). On the other hand, our data provide
evidence of an additive effect of NT-
proBNP and micro- and macroalbuminu-
ria in predicting the risk of CV mortality,
and this suggests that the parallel assess-
ment of both AER and NT-proBNP may
provide additional information for risk
stratification.
Identification of new biomarkers for
CV risk assessment is of particular im-
portance in diabetic patients without
micro- or macroalbuminuria. Our data
showing that normoalbuminuric patients
without CVD had a fivefold higher risk of
CV mortality when NT-proBNP values
were.91 pg/mL indicate that NT-proBNP
may be a promising prognostic marker in
this relevant subgroup of diabetic pa-
tients. Consistent with this result, in the
normoalbuminuric subgroup of theDanish
study elevated NT-proBNP levels were
significantly associated with increased
CV mortality, thought people with and
without baseline CVDwere not examined
separately (7).
Our data do not allow inferences about
causality of the relationship between
NT-proBNP and CV mortality. However,
causality is more likely if the response
is graded and multiple adjustments
for potential confounders/mediators
do not modify results as observed in our
study. Left ventricular hypertrophy
(LVH) and silent ischemia, leading to
subclinical cardiac stress, may link
NT-proBNP and CV mortality. Indeed, in-
creased values of BNP have been found
to be associated with increased LVH and
Table 3dHRs of 5-year all-cause and CV mortality in persons with type 2 diabetes of the Casale Monferrato study by AER and NT-proBNP
values
All-cause mortality HR (95% CI) CV mortality HR (95% CI)
AER ,20 mg/min AER $20 mg/min AER ,20 mg/min AER $20 mg/min
All patients*
NT-proBNP ,91 pg/mL 1.00 0.94 (0.54–1.64) 1.00 1.78 (0.59–5.39)
NT-proBNP $91 pg/mL 1.59 (1.06–2.39) 2.81 (1.85–4.67) 4.98 (2.17–11.43) 6.90 (2.92–16.28)
Patients without CVD**
NT-proBNP ,91 pg/mL 1.00 1.55 (0.89–2.71) 1.00 3.71 (1.17–11.72)
NT-proBNP $91 pg/mL 1.97 (1.26–3.06) 3.94 (2.52–6.15) 4.69 (1.76–12.49) 7.81 (2.87–21.28)
*HRs adjusted for age, sex, diabetes duration, BMI, hypertension (yes/no), apoB/apoA1, HbA1c, smoking (no, former, current), CVDs (yes/no), eGFR (,60 or$60
mL/min/1.73 m2), diabetes treatment (diet/oral drugs/insulin), and CRP. **HRs were adjusted for age, sex, and diabetes duration.
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deteriorated diastolic function in an
8-year follow-up, particularly in diabetic
patients (18). In addition, we have re-
cently reported that, in type 1 diabetic
patients from the EURODIAB case-control
study, the association betweenNT-proBNP
and vascular complications was depen-
dent on tumor necrosis factor (TNF)-a,
suggesting a role for TNF-a in linking
NT-proBNP to CVD (15). Recently,
an independent association between
NT-proBNP and TNF-a has also been
reported in hypertensive patients with
LVH (19). However, the underlying
molecular mechanisms remains uncer-
tain.
Strengths of this study are the pro-
spective design; the recruitment of a large
population-based cohort of type 2 di-
abetic people, increasing both precision
and generalizability; the centralized as-
sessment of CV risk factors and biomark-
ers, allowing analysis of the potential
confounding effect of covariates; and the
high degree of completeness of follow-up
data. There are, however, certain limita-
tions. Only 56% patients of the original
population-based cohort were recruited
in the study, and they were younger than
unrecruited people. As age was positively
correlated with NT-proBNP, the asso-
ciation between NT-proBNP and mortal-
ity might have been even greater in the
entire cohort. However, we cannot ex-
clude the possibility that risk factors
negatively associated with NT-proBNP,
such as BMI, might have acted in the
opposite direction in unrecruited pa-
tients. Our results are based on an obser-
vational prospective cohort and, though
multivariate methods of analyses were
used to control for the effect of known
confounders in the relationship between
NT-proBNP and mortality, we cannot
rule out the possibility of residual or un-
detected confounding effects on our re-
sults. A single NT-proBNP measurement
was performed using stored samples col-
lected at baseline. Although the stability
of NT-proBNP after long-term storage is
unknown, all samples were treated and
stored under the same conditions. The
study is based on a cohort of elderly
subjects and, though this is a group of
coniderable clinical interest because
they constitute a high-risk group in
whom traditional risk factors become
less predictive (20), our results need fur-
ther confirmation in similar middle-aged
populations. Finally, no data on struc-
tural and functional cardiac abnormali-
ties were available.
In conclusion, this study shows that
NT-proBNP is a strong independent pre-
dictor of short-term mortality risk in
elderly people with type 2 diabetes, even
in those without CVD at baseline. The
association between NT-proBNP and
mortality is additive to that provided by
AER, is not modified by CRP, and is
evident even in people with slightly in-
creased values, suggesting its role as an
early marker of vascular abnormalities.
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